We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

98 hedge funds and large institutions have $79.5M invested in CytomX Therapeutics in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 28 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 28

12.42% less ownership

Funds ownership: 82.07% → 69.65% (-12%)

18% less funds holding

Funds holding: 119 → 98 (-21)

45% less capital invested

Capital invested by funds: $143M → $79.5M (-$63.8M)

48% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 40

Holders
98
Holders Change
-21
Holders Change %
-17.65%
% of All Funds
1.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
21
Increased
26
Reduced
28
Closed
40
Calls
$37K
Puts
–
Net Calls
+$37K
Net Calls Change
+$8K

Top Buyers

Rank Fund Capital Flow
1
LCM
Laurion Capital Management
New York
+$2.43M
2
NM
Newtyn Management
New York
+$2.06M
3
TCM
Tang Capital Management
California
+$2.02M
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$1.83M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.07M

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$6.06M
2
RI
RTW Investments
New York
-$5.61M
3
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
-$3.45M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.1M
5
State Street
State Street
Massachusetts
-$1.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
51
Bank of New York Mellon
New York
$66K -$337K -176,108 -83%
LPL Financial
52
LPL Financial
California
$64K +$66.5K +34,740 New
Franklin Resources
53
Franklin Resources
California
$62K -$31.8K -16,595 -33%
AG
54
Algert Global
California
$56K +$58.1K +30,340 New
EGM
55
Engineers Gate Manager
New York
$51K +$172 +90 +0.3%
SOW
56
State of Wyoming
Wyoming
$43K +$45.4K +23,709 New
LP
57
LMR Partners
United Kingdom
$42K +$44.3K +23,134 New
BFM
58
Boothbay Fund Management
New York
$37K +$13.3K +6,953 +53%
AA
59
AlphaMark Advisors
Kentucky
$37K +$32.5K +17,000 +567%
Prudential Financial
60
Prudential Financial
New Jersey
$36K +$37.7K +19,700 New
BNP Paribas Financial Markets
61
BNP Paribas Financial Markets
France
$35.4K +$26.5K +13,864 +254%
Bank of America
62
Bank of America
North Carolina
$34K +$6.79K +3,548 +24%
WFA
63
WestHill Financial Advisors
California
$31K – – –
Balyasny Asset Management
64
Balyasny Asset Management
Illinois
$30K +$31.7K +16,552 New
Mackenzie Financial
65
Mackenzie Financial
Ontario, Canada
$29K +$4.59K +2,399 +18%
Osaic Holdings
66
Osaic Holdings
Arizona
$28K +$28.8K +15,039 +4,627%
Lazard Asset Management
67
Lazard Asset Management
New York
$27K – – –
GCM
68
Gladius Capital Management
Illinois
$25K +$25.2K +13,172 New
IIA
69
IPG Investment Advisors
California
$23K – – –
AGM
70
Alpine Global Management
New York
$22K – – –
TRCT
71
Tower Research Capital (TRC)
New York
$21K -$25.5K -13,319 -54%
CHAM
72
Clear Harbor Asset Management
Connecticut
$21K – – –
OQS
73
Occudo Quantitative Strategies
Florida
$20K +$20.7K +10,808 New
QT
74
Quantbot Technologies
New York
$17K -$30.1K -15,700 -62%
CSS
75
Cubist Systematic Strategies
Connecticut
$17K – – –
1 2
3
4 5

CTMX Hedge Fund Activity: Q2 2022 in Review

98 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2022, worth a combined $79.5M — down 45% from $143M a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of CTMX and 21 opened new positions — a net loss of 19 holders — while 28 trimmed existing stakes and 26 added.

The largest buyer was Laurion Capital Management, opening a new position worth an estimated $2.43M. The largest seller was BlackRock, cutting an estimated $6.06M.

  • 98 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2022, down from 119 in Q1 2022.
  • Funds reported $79.5M of CytomX Therapeutics stock for Q2 2022, down 45% quarter-over-quarter.
  • 21 funds opened new CytomX Therapeutics positions in Q2 2022 and 40 closed out, a net change of -19 holders.
  • The largest CytomX Therapeutics buyer in Q2 2022 was Laurion Capital Management, an estimated $2.43M added.
  • The largest CytomX Therapeutics seller in Q2 2022 was BlackRock, an estimated $6.06M sold.

Based on aggregated 13F filings for Q2 2022.